Emergency contraception options: what the latest evidence adds

Emergency contraception options are not interchangeable. The pills and devices used after unprotected sex differ in how reliably they prevent pregnancy, how long after sex they can be used, how they interact with ongoing hormonal contraception and how readily they can be obtained.

A new review drawing on 87 trials reports that emergency contraception containing mifepristone prevented more pregnancies than some commonly used pills, including levonorgestrel, while also producing fewer side effects in the comparisons assessed. The finding strengthens the case for treating emergency contraception as a choice among methods, rather than as one standard pill. It does not, however, mean that mifepristone is available or approved for this purpose in every country.

How emergency contraception options differ

Levonorgestrel is one of the most familiar emergency contraceptive pills. It works mainly by delaying or preventing ovulation and is most effective when taken as soon as possible. Availability without a prescription in many settings is a major practical advantage because delays can reduce effectiveness.

Ulipristal acetate is another established option. It can be used up to five days after unprotected sex and generally remains more effective than levonorgestrel later in that window. Because ulipristal acts on progesterone receptors, starting or restarting progestogen-containing contraception too soon afterward may reduce its effect. Guidance commonly advises waiting five days before resuming hormonal contraception, then using barrier protection for the recommended interval.

Mifepristone also acts at progesterone receptors. It is best known for its use in medication abortion at different doses and in a different clinical context, but low-dose mifepristone has also been studied and used for emergency contraception in some countries. The new review suggests that it may outperform levonorgestrel and certain other oral approaches. Regulatory approval, dosing protocols and access vary considerably, so the evidence cannot be translated into a universal pharmacy choice.

A copper intrauterine device is another highly effective form of emergency contraception when inserted within the appropriate timeframe. It also provides continuing contraception. A levonorgestrel-releasing intrauterine device may be offered for emergency contraception under some clinical guidelines, although recommendations and supporting evidence vary by jurisdiction.

What the mifepristone evidence can and cannot show

A review of 87 trials offers a broader evidence base than any single study. Pooling research can clarify differences that individual trials are too small to detect and can help compare pregnancy prevention, adverse effects and acceptability across methods.

The headline result still requires context. Trials may use different mifepristone doses, treatment windows, comparator pills and definitions of outcomes. Some studies may have been conducted in health systems where access, average time to treatment and patterns of contraceptive use differ from current practice elsewhere. Review-level findings describe average effects across studied groups; they do not guarantee the same result for every person or setting.

Fewer reported side effects is relevant because nausea, headache, abdominal discomfort, fatigue and changes in bleeding can influence whether a method feels acceptable. Yet side-effect comparisons depend on how symptoms were measured and how long participants were followed. A later or earlier next period can occur after emergency contraception and does not by itself establish whether treatment worked.

The review also raises an access question. A method cannot improve outcomes if regulation, prescribing rules, cost or stigma keep it out of reach. Mifepristone’s association with abortion care can shape policy even when it is being considered for the distinct purpose of preventing pregnancy after sex. Clinical evidence and legal availability therefore remain separate issues.

Timing, ovulation and body weight matter

Oral emergency contraception generally works by disrupting ovulation before it happens. It does not end an established pregnancy. This makes cycle timing important, but estimating ovulation from an app, calendar or remembered period date is imprecise. Ovulation can shift with stress, illness, travel, sleep disruption and ordinary cycle variability.

Taking an oral method promptly is therefore more useful than waiting for certainty about cycle phase. If ovulation has already occurred, oral pills may be less effective, while a copper intrauterine device can still offer strong protection when used within guideline-defined timing.

Body weight and body mass index may also affect the performance of oral emergency contraception, particularly levonorgestrel, although studies have not produced perfectly consistent thresholds. Some guidelines favor ulipristal acetate or an intrauterine device at higher body weights. The appropriate choice depends on timing, medication interactions, medical suitability and local guidance, not weight alone.

Enzyme-inducing medicines and herbal products can lower concentrations of oral emergency contraceptives. Examples include some treatments for epilepsy, tuberculosis and HIV, as well as St John’s wort. In these circumstances, a clinician or pharmacist may recommend a non-oral option or a locally approved alternative strategy.

What to expect after taking emergency contraception

Bleeding patterns can change after an emergency contraceptive pill. The next period may arrive earlier or later, and spotting can occur. These effects can overlap with usual cycle variation, which makes a single symptom difficult to interpret.

Pregnancy testing is important if the next period is substantially late, unusually light or absent, or if three weeks have passed since unprotected sex. New severe lower abdominal pain, fainting or persistent heavy bleeding warrants prompt medical assessment because pregnancy complications, although uncommon, need to be excluded. Emergency contraception does not protect against sexually transmitted infections, and it does not cover additional unprotected sex later in the cycle unless the chosen method also provides ongoing contraception.

Access remains part of effectiveness. The best-supported option on paper may not be the fastest available option in practice. A pharmacist, sexual health service or clinician can help compare timing, interactions, intrauterine-device suitability and when regular contraception can resume.

Cycle timing, bleeding changes and symptoms after emergency contraception only become readable as personal patterns when logged consistently over weeks. This is the kind of pattern Tulsy is built to surface.

Sources: Medical Xpress.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.